Update on Approved Osteoporosis Therapies Including Combination and Sequential Use of Agents

被引：7
作者：
Saul, Dominik [1 ,2 ,3 ]
Drake, Matthew T. [1 ,2 ]
机构：
[1] Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA
[2] Mayo Clin, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA
[3] Univ Gottingen, Dept Trauma Surg Orthopaed & Plast Surg, Robert Koch Str 40, D-37075 Gottingen, Germany
来源：
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2021年 / 50卷 / 02期
关键词：
Osteoporosis; Postmenopausal; Bone; Anti-resorptive; Anabolic; Combination; Sequential; BONE-MINERAL DENSITY; FRACTURE RISK REDUCTION; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; ZOLEDRONIC ACID; RANDOMIZED-TRIAL; TERIPARATIDE; DENOSUMAB; ALENDRONATE; RISEDRONATE;
D O I：
10.1016/j.ecl.2021.03.010
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：179 / 191
页数：13
相关论文
共 57 条
  • [1] Denosumab and bisphosphonates: Different mechanisms of action and effects
    Baron, Roland
    Ferrari, Serge
    Russell, R. Graham G.
    [J]. BONE, 2011, 48 (04) : 677 - 692
  • [2] Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial
    Bilezikian, John P.
    Hattersley, Gary
    Mitlak, Bruce H.
    Hu, Ming-Yi
    Fitzpatrick, Lorraine A.
    Dabrowski, Christine
    Miller, Paul D.
    Papapoulos, Socrates E.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (12) : 2097 - 2102
  • [3] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    Black, Dennis M.
    Delmas, Pierre D.
    Eastell, Richard
    Reid, Ian R.
    Boonen, Steven
    Cauley, Jane A.
    Cosman, Felicia
    Lakatos, Peter
    Leung, Ping Chung
    Man, Zulema
    Mautalen, Carlos
    Mesenbrink, Peter
    Hu, Huilin
    Caminis, John
    Tong, Karen
    Rosario-Jansen, Theresa
    Krasnow, Joel
    Hue, Trisha F.
    Sellmeyer, Deborah
    Eriksen, Erik Fink
    Cummings, Steven R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) : 1809 - 1822
  • [4] Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
    Black, Dennis M.
    Schwartz, Ann V.
    Ensrud, Kristine E.
    Cauley, Jane A.
    Levis, Silvina
    Quandt, Sara A.
    Satterfield, Suzanne
    Wallace, Robert B.
    Bauer, Douglas C.
    Palermo, Lisa
    Wehren, Lois E.
    Lombardi, Antonio
    Santora, Arthur C.
    Cummings, Steven R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24): : 2927 - 2938
  • [5] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
    Black, DM
    Cummings, SR
    Karpf, DB
    Cauley, JA
    Thompson, DE
    Nevitt, MC
    Bauer, DC
    Genant, HK
    Haskell, WL
    Marcus, R
    Ott, SM
    Torner, JC
    Quandt, SA
    Reiss, TF
    Ensrud, KE
    [J]. LANCET, 1996, 348 (9041) : 1535 - 1541
  • [6] ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
    Bone, Henry G.
    Cosman, Felicia
    Miller, Paul D.
    Williams, Gregory C.
    Hattersley, Gary
    Hu, Ming-yi
    Fitzpatrick, Lorraine A.
    Mitlak, Bruce
    Papapoulos, Socrates
    Rizzoli, Rene
    Dore, Robin K.
    Bilezikian, John P.
    Saag, Kenneth G.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (08) : 2949 - 2957
  • [7] 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
    Bone, Henry G.
    Wagman, Rachel B.
    Brandi, Maria L.
    Brown, Jacques P.
    Chapurlat, Roland
    Cummings, Steven R.
    Czerwinski, Edward
    Fahrleitner-Pammer, Astrid
    Kendler, David L.
    Lippuner, Kurt
    Reginster, Jean-Yves
    Roux, Christian
    Malouf, Jorge
    Bradley, Michelle N.
    Daizadeh, Nadia S.
    Wang, Andrea
    Dakin, Paula
    Pannacciulli, Nicola
    Dempster, David W.
    Papapoulos, Socrates
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) : 513 - 523
  • [8] Osteoporosis Therapy in Postmenopausal Women With High Risk of Fracture
    Cappola, Anne R.
    Shoback, Dolores M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (07): : 715 - 716
  • [9] Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
    Chesnut, CH
    Skag, A
    Christiansen, C
    Recker, R
    Stakkestad, JA
    Hoiseth, A
    Felsenberg, D
    Huss, H
    Gilbride, J
    Schimmer, RC
    Delmas, PD
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) : 1241 - 1249
  • [10] Romosozumab Treatment in Postmenopausal Women with Osteoporosis
    Cosman, F.
    Crittenden, D. B.
    Adachi, J. D.
    Binkley, N.
    Czerwinski, E.
    Ferrari, S.
    Hofbauer, L. C.
    Lau, E.
    Lewiecki, E. M.
    Miyauchi, A.
    Zerbini, C. A. F.
    Milmont, C. E.
    Chen, L.
    Maddox, J.
    Meisner, P. D.
    Libanati, C.
    Grauer, A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (16) : 1532 - 1543
123456